| 不同HER-2状态的进展期胃癌行紫杉醇联合希罗达的疗效分析 |
| |
| 引用本文： | 肖莉,任建林,王馨,张秋华,吕霞.不同HER-2状态的进展期胃癌行紫杉醇联合希罗达的疗效分析[J].中国肿瘤临床,2012,39(15):1108-1110. |
| |
| 作者姓名： | 肖莉 任建林 王馨 张秋华 吕霞 |
| |
| 作者单位： | 厦门大学附属中山医院肿瘤科（福建省厦门市361004） |
| |
| 摘 要： | 目的 既往体外实验显示HER-2的表达与紫杉醇疗效呈负相关, 本研究初步评价不同HER-2状态的进展期胃癌行紫杉醇联合希罗达的临床疗效。 方法 2010年6月至2012年2月厦门大学附属中山医院肿瘤科收治病理确诊的进展期胃癌45例, 其中HER-2(+)20例, HER-2(-)25例, 均接受紫杉醇联合卡培他滨联合化疗。紫杉醇175 mg/m2, d1;卡培他滨2 g/m2, d1~14, 21d为1个周期, 至少化疗2个周期后按RECIST标准判定疗效及不良反应。 结果 入组45例患者中, HER-2(+)组5例CR, 8例PR, 4例SD, 3例PD。HER-2(-)组0例CR, 10例PR, 7例SD, 8例PD。进行Kruskal Wallis法H检验(P=0.026)。 结论 HER-2受体的状态与进展期胃癌紫杉醇化疗敏感性相关, HER-2(+)组的化疗疗效优于HER-2(-)组。HER-2可能成为理想的抗肿瘤药物的分子标志。
|
| 关 键 词： | HER-2 紫杉醇 进展期胃癌 |
| 收稿时间： | 2012-04-02 |
Efficacy of Paclitaxel plus Capecitabine for Advanced Gastric Cancer with Different HER-2 Status |
| |
| Li XIAO
,
Jianlin REN
,
XinWANG
,
Qiuhua ZHANG
,
Xia LV.Efficacy of Paclitaxel plus Capecitabine for Advanced Gastric Cancer with Different HER-2 Status[J].Chinese Journal of Clinical Oncology,2012,39(15):1108-1110. |
| |
| Authors: | Li XIAO Jianlin REN XinWANG Qiuhua ZHANG Xia LV |
| |
| Affiliation: | Department of Oncology, Zhongshan Hospital Affiliated to Xiamen University, Xiamen 361004, China |
| |
| Abstract: | Objective To analyze the efficacy of paclitaxel plus capecitabine against advanced gastric cancer with different HER-2 status. Method A total of 45 advanced gastric cancer cases, as confirmed through histopathology, treated in our department since June 2010 were enrolled into the study. Up to 20 cases were included in the HER-2 (+) group and 25 were included in the HER-2 (-) group. All patients received paclitaxel plus capecitabine chemotherapy (175 mg/m2 paclitaxel on and 2 g/m2 capecitabine on d 1 for 14 d to 21 d per cycle). In all cases, the efficacy and toxicity of the chemotherapy were determined at least after two cycles, according to the RECIST criteria. Results The 45 patients were evaluated for efficacy and adverse reactions. In the HER-2 (+) group, 5 cases achieved complete remission (CR), 8 achieved partial remission (PR), 4 had stable disease (SD), and 3 cases had progressive disease (PD). In the HER-2 (-) group, 0 cases achieved CR, 10 achieved PR, 7 had SD, and 8 cases had PD (Kruskal-Wallis H test, P = 0.026). Conclusion HER-2 receptor expression is related to the sensitivity of paclitaxel in advanced gastric cancer. The efficacy of the treatment in the HER-2 (+) group is better than that in the HER-2 (-) group. The results contradict previous in vitro findings. HER-2 may be an ideal means of transporting anticancer drugs. |
| |
| Keywords: | |
| 本文献已被 CNKI 万方数据 等数据库收录！ |
| 点击此处可从《中国肿瘤临床》浏览原始摘要信息 |
|
点击此处可从《中国肿瘤临床》下载全文 |
|
